The authors suggest targeting peripheral pathways may modify AD outcomes, but the causal relationships and intervention mechanisms are undefined. Understanding these pathways is critical for developing peripheral biomarker-guided therapies. Gap type: open_question Source paper: Plasma proteomic associations with Alzheimer's disease endophenotypes. (2025, Nature aging, PMID:40931114)
Landscape Summary: How do peripheral pathway interventions modify AD risk or progression through plasma protein changes? is a 0.8 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
How do peripheral pathway interventions modify AD risk or progression through plasma protein changes? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: